Construction of a new isovalerylspiramycin I producing strain by CRISPR-Cas9 system.
- Author:
Xiaoting ZHANG
1
;
Yan ZHANG
2
;
Jianlu DAI
1
;
Yiguang WANG
1
;
Weiqing HE
1
Author Information
- Publication Type:Journal Article
- Keywords: CRISPR-Cas9 system; IsovalerylspiramycinⅠ; acyltransferase gene
- MeSH: CRISPR-Cas Systems; Gene Editing; Genetic Engineering; Homologous Recombination
- From: Chinese Journal of Biotechnology 2019;35(3):472-481
- CountryChina
- Language:Chinese
- Abstract: Isovalerylspiramycin (ISP)Ⅰ, as a major component of bitespiramycin (BT), exhibits similar antimicrobial activities with BT and has advantages in quality control and dosage forms. It has been under preclinical studies. The existing ISPⅠ producing strain, undergoing three genetic modifications, carries two resistant gene markers. Thus, it is hard for further genetic manipulation. It is a time-consuming and unsuccessful work to construct a new ISPⅠ strain without resistant gene marker by means of the classical homologous recombination in our preliminary experiments. Fortunately, construction of the markerless ISPⅠ strain, in which the bsm4 (responsible for acylation at 3 of spiramycin) gene was replaced by the Isovaleryltansferase gene (ist) under control of the constitutive promoter ermEp*, was efficiently achieved by using the CRISPR-Cas9 gene editing system. The mutant of bsm4 deletion can only produce SPⅠ. Isovaleryltransferase coded by ist catalyzes the isovalerylation of the SPⅠat C-4" hydroxyl group to produce ISPⅠ. As anticipated, ISPⅠ was the sole ISP component of the resultant strain (ΔEI) when detected by HPLC and mass spectrometry. The ΔEI mutant is suitable for further genetic engineering to obtain improved strains by reusing CRISPR-Cas9 system.
